1. Home
  2. GBIO vs OKUR Comparison

GBIO vs OKUR Comparison

Compare GBIO & OKUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • OKUR
  • Stock Information
  • Founded
  • GBIO 2016
  • OKUR 2011
  • Country
  • GBIO United States
  • OKUR United States
  • Employees
  • GBIO 115
  • OKUR N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • OKUR
  • Sector
  • GBIO Health Care
  • OKUR
  • Exchange
  • GBIO Nasdaq
  • OKUR NYSE
  • Market Cap
  • GBIO 29.2M
  • OKUR 34.9M
  • IPO Year
  • GBIO 2020
  • OKUR N/A
  • Fundamental
  • Price
  • GBIO $0.36
  • OKUR $1.92
  • Analyst Decision
  • GBIO Strong Buy
  • OKUR Strong Buy
  • Analyst Count
  • GBIO 4
  • OKUR 4
  • Target Price
  • GBIO $7.33
  • OKUR $32.25
  • AVG Volume (30 Days)
  • GBIO 493.7K
  • OKUR 66.2K
  • Earning Date
  • GBIO 05-07-2025
  • OKUR 05-06-2025
  • Dividend Yield
  • GBIO N/A
  • OKUR N/A
  • EPS Growth
  • GBIO N/A
  • OKUR N/A
  • EPS
  • GBIO N/A
  • OKUR N/A
  • Revenue
  • GBIO $24,556,000.00
  • OKUR N/A
  • Revenue This Year
  • GBIO N/A
  • OKUR N/A
  • Revenue Next Year
  • GBIO $10.90
  • OKUR N/A
  • P/E Ratio
  • GBIO N/A
  • OKUR N/A
  • Revenue Growth
  • GBIO 146.47
  • OKUR N/A
  • 52 Week Low
  • GBIO $0.32
  • OKUR $1.98
  • 52 Week High
  • GBIO $4.34
  • OKUR $20.00
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 39.03
  • OKUR N/A
  • Support Level
  • GBIO $0.36
  • OKUR N/A
  • Resistance Level
  • GBIO $0.41
  • OKUR N/A
  • Average True Range (ATR)
  • GBIO 0.04
  • OKUR 0.00
  • MACD
  • GBIO -0.00
  • OKUR 0.00
  • Stochastic Oscillator
  • GBIO 9.09
  • OKUR 0.00

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About OKUR ONKURE THERAPEUTICS INC

OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.

Share on Social Networks: